Skip to main content
Pharmacokinetics of ceftiofur crystalline-free acid following subcutaneous administration of a single dose to sheep.
- Author(s): Rivera-Garcia, Sarai;
- Angelos, John A;
- Rowe, Joan D;
- Byrne, Barbara A;
- Wetzlich, Scott E;
- Van Liew, Dana B;
- Tell, Lisa A
- et al.
Published Web Locationhttps://doi.org/10.2460/ajvr.75.3.290
ObjectiveTo determine the pharmacokinetics of ceftiofur crystalline-free acid (CCFA) following SC administration of a single dose to sheep.
Animals9 healthy adult female Suffolk-crossbred sheep.
ProceduresEach sheep was administered 6.6 mg of CCFA/kg, SC, in the cervical region once. Serial blood samples were collected at predetermined intervals for 14 days. Serum concentration of ceftiofur free-acid equivalents (CFAE) was determined by high-performance liquid chromatography. Pharmacokinetic parameters were determined by compartmental and noncompartmental methods.
ResultsPharmacokinetics for CCFA following SC administration in sheep was best described with a 1-compartment model. Mean ± SD area under the concentration-time curve from time 0 to infinity, peak serum concentration, and time to peak serum concentration were 206.6 ± 24.8 μ•h/mL, 2.4 ± 0.5 μg/mL, and 23.1 ± 10.1 h, respectively. Serum CFAE concentrations ≥ 1 μg/mL (the target serum CFAE concentration for treatment of disease caused by Mannheimia haemolytica and Pasteurella multocida) were maintained for 2.6 to 4.9 days. No significant adverse reactions to CCFA administration were observed.
Conclusions and clinical relevanceResults indicated that adequate therapeutic serum concentrations of CFAE for treatment of disease caused by M haemolytica and P multocida were achieved in sheep following SC administration of a single dose (6.6 mg/kg) of CCFA. Thus, CCFA might be useful for the treatment of common respiratory tract pathogens in sheep.
For improved accessibility of PDF content, download the file to your device.